Dec. 18, 2024 — Research has uncovered a vulnerability in prostate cancer animal models that starves prostate tumors of critical nutrients and stunts their growth, which could lead to the ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...

Advanced Imaging Uncovers Hidden Metastases in High-Risk Prostate Cancer Cases Jan. 3, 2025 — A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer ...

Medscape Medical News, June 06, 2019 ASCO 2019 More Is Not Better in Metastatic CR Prostate Cancer The combination of enzalutamide plus abiraterone is not more effective than enzalutamide alone ...

Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival.

Here the authors report the results of a phase 1 trial of PSCA-directed autologous CAR-T cells with pharmacological activation by rimiducid in patients with metastatic pancreatic or prostate cancer.

Background: In this population-based study, we investigated the degree of concordance between Gleason scores obtained from prostate biopsies and those obtained from prostatectomy specimens, as ...

In 2004, the chemotherapy agent docetaxel was approved for the treatment of metastatic prostate cancer. Although it has taken almost a decade, significant new advances have been made in this area ...

No writing assistance was utilized in the production of this manuscript. Prostate cancer (PCa) is associated with a high economic burden in the USA. Several novel treatments for PCa have been ...

CEO of Bayer UK & Ireland, Antonio Payano, said: “We are delighted that men with prostate cancer in England will have early access to another innovative treatment option.

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 ...